Publications :: Actinium Pharmaceuticals, Inc. (ATNM)

Tumor therapy with targeted atomic nanogenerators..

McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. C, Molinet R.
Science. 2001 Nov 16;294(5546):1537-40.
PMID: 11711678

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. Cancer Res. 2000 Nov 1;60(21):6095-100. [MEDLINE record in process]
PMID: 11085533; UI: 20535983

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. Cancer Res. 2000 Sep 15;60(18):5237-43.
PMID: 11016653; UI: 20468868

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA.
J Nucl Med. 1999 Nov;40(11):1935-46.
PMID: 10565792; UI: 20029522

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA.
J Nucl Med. 1999 Oct;40(10):1722-7.
PMID: 10520715; UI: 99449025

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.

McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA.
Appl Radiat Isot. 1999 May;50(5):895-904.
PMID: 10214708; UI: 99231323

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.

Kaspersen FM, Bos E, Doornmalen AV, Geerlings MW, Apostolidis C, Molinet R.
Nucl Med Commun. 1995 Jun;16(6):468-76.
PMID: 7675360; UI: 95405762

Radioimmunotherapy with alpha-emitting nuclides.

McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA.
Eur J Nucl Med. 1998 Sep;25(9):1341-51. Review.
PMID: 9724387; UI: 98391728

Radionuclides for radioimmunotherapy: criteria for selection.

Geerlings MW.
Int J Biol Markers. 1993 Jul-Sep;8(3):180-6.
PMID: 8277210; UI: 94103681

The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.

Geerlings MW, Kaspersen FM, Apostolidis C, van der Hout R.
Nucl Med Commun. 1993 Feb;14(2):121-5.
PMID: 8429990; UI: 93157017

Publications